REV7 associates with ATRIP and inhibits ATR kinase activity
Nucleic Acids Research · 2026
DOI: 10.1093/nar/gkaf1527 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2026. Verfasst von Megan Biller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC 28223, United States. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, DNA-Binding Proteins, Adaptor Proteins, Signal Transducing, Cell Cycle Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Astellas Research Foundation, NIEHS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Ataxia-telangiectasia mutated and RAD3-related (ATR) and its partner ATR-interacting protein (ATRIP) function as a critical proximal sensor and transducer of the DNA damage response (DDR). Several ATR substrates, including p53 and CHK1, are crucial for the coordination of cell cycle phase transitions, transcription, and DNA repair when cells sustain DNA damage. While much is known about ATR activation mechanisms, it is less clear how ATR signaling is negatively regulated in cells. Here, we identify the DNA repair protein REV7 as a novel direct binding partner of ATRIP. We define a REV7-interaction motif in ATRIP, which, when mutated, abrogates the REV7–ATRIP interaction in vitro and in intact cells. Using in vitro kinase assays, we show that REV7 inhibits ATR-mediated phosphorylation of its substrates, including p53. Disruption of the REV7–ATRIP interaction also enhances phosphorylation of CHK1 at Ser317 in intact cells. Taken together, our results establish REV7 as a critical negative regulator of ATR signaling. REV7 has pleiotropic roles in multiple DDR pathways, including Translesion Synthesis, DNA double-strand break resection, and p53 stability and may play a central role in the integration of multiple genome maintenance pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC 28223, United States.
- Department of Genome Medicine, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
- Department of Biochemistry, Duke University School of Medicine, Durham, NC 27710, United States.
- Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, United States.
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, United States.
ORCID-Profile: Hiroyuki Sasanuma, Junya Tomida
Förderung
- Astellas Research Foundation
- NIEHS NIH HHS
- NCI NIH HHS
- Takeda Bioscience Research
- NIH HHS
- Mitsubishi Research
- Naito Research
- Japan Society for the Promotion of Science
Zitieren
APA
Biller, M., Kabir, S., Nipper, S., Allen, S., Kayali, Y., Kuncik, S., Sasanuma, H., Zhou, P., Vaziri, C., & Tomida, J. (2026). REV7 associates with ATRIP and inhibits ATR kinase activity. Nucleic Acids Research. https://doi.org/10.1093/nar/gkaf1527
Vancouver
Biller M, Kabir S, Nipper S, Allen S, Kayali Y, Kuncik S, et al. REV7 associates with ATRIP and inhibits ATR kinase activity. Nucleic Acids Research. 2026. doi:10.1093/nar/gkaf1527
BibTeX
@article{Biller2026,
author = {Biller, Megan and Kabir, Sara and Nipper, Sarah and Allen, Sydney and Kayali, Yara and Kuncik, Skyler and Sasanuma, Hiroyuki and Zhou, Pei and Vaziri, Cyrus and Tomida, Junya},
title = {REV7 associates with ATRIP and inhibits ATR kinase activity},
journal = {Nucleic Acids Research},
year = {2026},
doi = {10.1093/nar/gkaf1527}
}
EUVIMED